Medicis Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Scottsdale AZ United States (1988)
Status: Acquired by Bausch Health Companies (2012)

Organization Overview

First Clinical Trial
2005
NCT00765583
First Marketed Drug
1988
edetic acid
First NDA Approval
2013
luliconazole (luzu)
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MEDICIS | Medicis Global Service Corporation | Medicis Pharmaceutical | Medicis Pharmaceutical Corporation | MEDICIS PHARMS

Active Ingredients

Marketed Drugs (20)

Key: Medicis (16) Acquired (4)

acetylsalicylic acid (aspirin) (1964)

caffeine (1964)

ciclopirox (loprox) (2003)

clindamycin (cleocin) (2006)

doxycycline (vibramycin) (2005)

edetic acid (1953)

fluocinonide (lidex) (2005)

imiquimod (aldara) (1997)

luliconazole (luzu) (2013 NDA)

metronidazole (flagyl) (1992)

minocycline (minocin) (2006)

nitroglycerin (transderm-nitro) (1988)

orphenadrine hydrochloride (disipal) (1959)

phenylacetic acid (ucephan) (2005)

pirbuterol (maxair) (1992)

prednisolone (hydeltra) (2002)

sodium benzoate (AMMONUL) (2005)

theophylline (synophylate) (1980)

tretinoin (Retin-A) (2006)

urea (1981)

Drugs in Phase 4 Trials (17)

Key: Medicis (7) Acquired (10)

benzoyl peroxide (clearasil) (1 trial)

chlorhexidine (hibitane) (14 trials)

clindamycin (cleocin) (3 trials)

ethanol (2 trials)

flecainide (tambocor) (1 trial)

fluocinonide (lidex) (4 trials)

hyaluronic acid (2 trials)

imiquimod (aldara) (20 trials)

iodine (3 trials)

isopropyl alcohol (11 trials)

methylene blue (proveblue) (1 trial)

minocycline (minocin) (2 trials)

mupirocin (bactroban) (1 trial)

povidone-iodine (betadine) (3 trials)

rimabotulinumtoxinB (Myobloc) (4 trials)

sodium chloride (6 trials)

tretinoin (Retin-A) (3 trials)

Drugs in Phase 3 Trials (6)

Key: Medicis (1) Acquired (5)

budesonide (rhinocort) (1 trial)

diisopropyl adipate (1 trial)

formoterol (foradil) (1 trial)

luliconazole (luzu) (3 trials)

metronidazole (flagyl) (2 trials)

resorcinol (1 trial)

Drugs in Phase 2 Trials (3)

Key: Medicis (1) Acquired (2)

desoximetasone (topicort) (1 trial)

petrolatum, white (Vaseline) (1 trial)

resiquimod (6 trials)

Drugs in Phase 1 Trials (8)

Key: Medicis (0) Acquired (8)

bg505 sosip.664 gp140 (1 trial)

fluticasone (cutivate) (1 trial)

glycerol phenylbutyrate (ravicti) (2 trials)

phenylacetic acid (ucephan) (1 trial)

salmeterol (serevent) (1 trial)

sodium benzoate (AMMONUL) (1 trial)

sodium phenylbutyrate (buphenyl) (1 trial)

tiotropium (spiriva) (5 trials)

Drugs in Other Trials (4)

Key: Medicis (0) Acquired (4)

iodine povacrylex (DuraPrep Surgical) (2 trials)

pf-04878691 (1 trial)

sodium lauryl sulfate (1 trial)

water (1 trial)

Indications

Approved Indications


 

Tinea

Tinea Pedis

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 4)

Atrophy (Phase 4)

Dermatitis (Phase 4)

Dermatitis, Atopic (Phase 4)

Dermatitis, Seborrheic (Phase 2)

Eczema (Phase 4)

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Prolapse (Phase 4)

Rosacea (Phase 3)

Skin Neoplasms (Phase 4)

Tinea (Phase 3)

Tinea Pedis (Phase 3)

Vaginal Diseases (Phase 3)

Vaginosis, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 78
  • # of Trial APIs: 38